Quoin Pharmaceuticals (QNRX)
(Delayed Data from NSDQ)
$0.50 USD
+0.02 (4.15%)
Updated Aug 15, 2024 03:58 PM ET
After-Market: $0.49 -0.01 (-1.98%) 4:30 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
QNRX 0.50 +0.02(4.15%)
Will QNRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for QNRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QNRX
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
QNRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNRX
Maxim Group Sticks to Their Buy Rating for Quoin Pharmaceuticals (QNRX)
QNRX Stock Earnings: Quoin Pharmaceuticals Beats EPS for Q2 2024
Quoin Pharmaceuticals reports Q2 results
Quoin Pharmaceuticals reports Q2 EPS (39c), consensus (61c)
Quoin Pharmaceuticals initiates QRX003 study